Title :

Ceftobiprole: a potential empirical post-operative monotherapy in prosthetic joint infections.

Author(s) :

Duployez, Claire [Auteur]
Centre d’Infection et d’Immunité de Lille - INSERM U 1019 - UMR 9017 - UMR 8204 [CIIL]
Institut de Microbiologie [CHRU Lille]
Wallet, Frederic [Auteur]
Centre d'Infection et d'Immunité de Lille (CIIL) - U1019 - UMR 9017
Migaud, Henri [Auteur]
Marrow Adiposity & Bone Lab [MABLab] - ULR 4490
Marrow Adiposity & Bone Lab (MABLab) - ULR 4490
Senneville, Eric [Auteur]
METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694
Loiez, Caroline [Auteur]
Centre d’Infection et d’Immunité de Lille - INSERM U 1019 - UMR 9017 - UMR 8204 [CIIL]
Institut de Microbiologie [CHRU Lille]

Journal title :

Annals of Clinical Microbiology and Antimicrobials

Abbreviated title :

Ann. Clin. Microbiol. Antimicrob.

Volume number :

19

Pages :

9

Publication date :

2020-03-28

ISSN :

1476-0711

English keyword(s) :

Prosthetic joint infection
Ceftobiprole
Empirical antibiotic therapy
Bacterial resistance

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

Background This study aimed to evaluate in vitro susceptibility to ceftobiprole of clinical strains identified from prosthetic joint infections (PJIs) compared to that of the associations currently recommended for ...
Show more >Background This study aimed to evaluate in vitro susceptibility to ceftobiprole of clinical strains identified from prosthetic joint infections (PJIs) compared to that of the associations currently recommended for post-operative empirical antibiotic therapy (PEAT) (vancomycin with either cefepime, third-generation cephalosporin or piperacillin–tazobactam). Methods We performed a 1-year retrospective study on all the surgical procedures performed in our hospital for PJI. Susceptibility profiles of all the strains cultured from surgical samples were reviewed to compare ceftobiprole to current used associations. Results During the study period (from January 2018 to December 2018), we identified 106 patients managed for PJI and a total of 216 surgical interventions. One hundred-fifty strains were identified from intraoperative samples, excluding redundant strains. Staphylococcus spp. represented 52.7% of all strains and Enterobacteriales 13.3%. Twenty-three patients had polymicrobial infection (22%). Among 149 surgical procedures with positive culture results, ceftobiprole covered the bacterial strains in 138 (92.6%) cases. In comparison, this percentage was 94.6% for vancomycin plus cefepime (p = 0.64), 92.6% for vancomycin plus a third-generation cephalosporin in 138 cases (p = 1) and 94.6% for vancomycin plus piperacillin–tazobactam) (p = 0.64). Conclusion Based on antimicrobial susceptibility testing, our results suggest that ceftobiprole could be an interesting option for PEAT in PJIs, allowing the use of a single agent.Show less >

Language :

Anglais

Audience :

Internationale

Popular science :

Non

Administrative institution(s) :

Université de Lille
CHU Lille

Collections :

• Centre d'Infection et d'Immunité de Lille (CIIL) - U1019 - UMR 9017
• Marrow Adiposity & Bone Lab (MABLab) - ULR 4490
• METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694

Submission date :

2023-11-15T09:09:04Z
2023-12-12T14:19:21Z